| HOME >> BIOLOGY >> TECHNOLOGY |
Selling, general and administrative (3) (3)
Total $2 $2
To adjust for the results of operations of our non-core DDD&I business
which is expected to be divested. The Company believes adjusting GAAP
earnings for this loss will allow investors to better assess our ongoing
activities.
(c) Amortization and inventory step up adjustments:
Cost of sales (95) (112)
Selling, general and administrative (1) -
Total $(96) $(112)
(d) Incremental PLIVA Depreciation due to purchase accounting write up
of fixed assets:
Cost of sales $(13) $(9)
Selling, general and administrative (1) (1)
Total $(14) $(10)
(e) Write off of acquired IPR&D associated with additional PLIVA shares
$- $(4)
(f) Product settlement - Sanctura $(53) $-
(g) Product Royalty contingency $(1) $-
(h) Litigation Reserve $(1) $(8)
(i) Adjustments to tax expense, including:
Tax impact of adjustments (a) - (h) above. $8 $36
Tax (benefit) from recognition of acquired
NOL - (5)
Total $8 $30
EBITDA (from continuing operations) Calculation:
Six Months Ended June 30,
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |